March 31, 2008 - MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), announced the initiation of a Phase II clinical trial, by holding the Investigator's Meeting, to determine the safety and efficacy of MN-221 in patients with severe, acute exacerbations of asthma. This randomized, modified single-blind, placebo-controlled, dose escalation Phase II clinical trial will involve approximately 36 patients in three dose cohorts at eight emergency department clinical sites in the U.S. and Puerto Rico. Each patient will receive MN-221 or placebo administered through a continuous infusion in addition to the standardized care treatment for an acute exacerbation of asthma. Once the patient has received the initial standardized care treatment regimen (consistent with the National Asthma Education and Prevention Program guidelines), the patient will be assessed for response to that treatment... MediciNova 's Press Release -
